Phase I Study of Safety and Pharmacokinetics of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors

Trial Profile

Phase I Study of Safety and Pharmacokinetics of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2016

At a glance

  • Drugs Sulfatinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 21 Mar 2016 Results were published in a Chi-Med media release.
    • 09 Nov 2015 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2015
    • 30 Oct 2015 Data will be presented at the 2015 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference, according to a Hutchison MediPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top